Microlearning Topics
Epidemiology of Diabetes
Impact of Diabetes
Diabetes Epidemiology
Diabetes: Age Distribution
Impact of Diabetes
Economic Burden of Diabetes
Diabetes Epidemiology
Diabetes: Geographical Distribution
Introduction to Diabetes and Diabetes Terminology
Diagnosing and Treating Diabetes
Introduction to Diabetes and Diabetes Terminology
Introduction to Diabetes and Diabetes Terminology
Summary: Diabetes
Summary: Diabetes
Introduction: Epidemiology of Diabetes
Introduction: Epidemiology of Diabetes
Diabetes Epidemiology
Prevalence of Undiagnosed Diabetes (2011)
Diabetes Epidemiology
Lifetime Risk for Diagnosis for Diabetes (US)
Diabetes Epidemiology
Worldwide Incidence of Type 1 Diabetes
Diabetes Epidemiology
Worldwide Prevalence of Diabetes
Diabetes: Geographical Distribution
Type 2 Diabetes: Introduction
Type 2 Diabetes: Introduction
Introduction: Diabetes Studies
Introduction: Diabetes Studies
Impact of Diabetes
Under Age Deaths
Diabetes Epidemiology
Prevalence of Type 1 Diabetes by IDF Region
Worldwide Incidence of Type 1 Diabetes
Diabete...
Epidemiology
SEARCH for Diabetes in Youth
Relationship between Obesity, Diabetes and Cardiovascular Disease
Obesity and Type 2 Diabetes: Youth
Epidemiology of Diabetes
Diabetic Neuropathy Negatively Affects Quality of Life Score
Relationship between Obesity, Diabetes and Cardiovascular Disease
Obesity, Diabetes and Cardiovascular Disease
Type 2 Diabetes Mellitus
Type 2 Diabetes (T2DM)
Impact of Diabetes
Economic Burden of Diabetes on Middle and Low Income Countries
Pathology of Type 2 Diabetes Mellitus
Etiology of Type 2 Diabetes
Epidemiology of Diabetes
Effect of Type 2 Diabetes and Obesity on Quality of Life Score
Relationship between Obesity, Diabetes and Cardiovascular Disease
Obesity and Type 2 Diabetes: Adults
Diabetes Epidemiology
Prevalence of Type 1 Diabetes by IDF Region
T1DM (Type 1 Diabetes)
Type 1 Diabetes Mellitus (T1DM)
Underlying Mechanisms of Diabetes Complications
Acute Complications of Diabetes
Microvascular Complications
Diabetic Neuropathy: Treatment, Diabetic Foot
Introduction: Pathology of Diabetes Complications
Acute Diabetes Complications
Natural History of Type 1 Diabetes
Progression of Type 1 Diabetes
Diabetes Epidemiology
Worldwide Prevalence of Diabetes
T1DM (Type 1 Diabetes)
Type 1 Diabetes Symptoms
Introduction: Pathology of Diabetes Complications
Chronic Diabetes Complications: Macrovascular and Diabetic Foot
Underlying Mechanisms of Diabetes Complications
Macrovascular Complications in Diabetes
Organs Affected by Diabetes
Organs Affected by Diabetes
Organs Affected by Diabetes
Organs Affected by Diabetes
Relationship between Obesity, Diabetes and Cardiovascular Disease
Obesity and Diabetes Risk
Microvascular Complications
Microvascular Complications in Diabetes
Disease State
Pathophysiology of Type 2 Diabetes
Microvascular Complications
Diabetic Neuropathy: Pathogenesis
Microvascular Complications
Diabetic Neuropathy
Diagnosis and Management
Diagnosing Type 2 Diabetes
Epidemiology of Diabetes
Impact of Diabetes
Effect of Type 2 Diabetes and Obesity on Quality of Life Score
Diabetic...
Organs Affected by Diabetes
Stomach
Osteoporosis and Diabetes
The Osteoporosis Diabetes Link
Anatomy and Physiology of Diabetes
Introduction: Anatomy and Physiology of Diabetes
Organs Affected by Diabetes
Eyes
Organs Affected by Diabetes
Kidneys
Organs Affected by Diabetes
Liver
Organs Affected by Diabetes
Heart
T2DM Diagnosis
Diagnostic of Diabetes
Impact of Diabetes
4 Out of 5 People with Diabetes Live in Low and Middle Income Countries
Natural History of Type 1 Diabetes
Differences in Type 1 Diabetes Mellitus
Epidemiology of Diabetes
Effect of Diabetes Duration on Life-Years and Quality Adjusted Life-Years Lost Among Females in the ...
Use of Incretin Therapies in Treating Type 2 Diabetes
ADA/EASD Treatment Recommendations for People with Type 2 Diabetes
Type 2 Diabetes Mellitus
Common Risk Factors for Type 2 Diabetes
Pathology of Type 2 Diabetes Mellitus
Natural History of Type 2 Diabetes
Natural History of Type 1 Diabetes
Natural History of Type 1 Diabetes
Diabetes Clinical Trials Studying Complications
UK Prospective Diabetes Study (UKPDS)
Clinical Trials: Cardiovascular Outcomes for Diabetes Drugs
Common Outcomes in Diabetes Trials
Impact of Diabetes
Deaths Attributable to Disease
4 Out of 5 People with Diabetes Live in Low and Middle Income Co...
Beta Cell Dysfunction in Type 2 Diabetes Mellitus
Beta Cell Dysfunction in Diabetes: Insulin Secretion
Introduction: Issues in Pediatric Diabetes
Introduction: Issues in Pediatric Diabetes
Pathology of T1DM
Type 1 Diabetes Disease Pathway: Islet Autoantibodies
Pathology of T1DM
Type 1 Diabetes: Risk Factors
Natural History of Type 1 Diabetes
Diagnosis
Overview of Pathophysiology and Treatment
Pathophysiology of Type 1 Diabetes
Diabetes Clinical Trials Studying Complications
DCCT/EDIC Study
Diabetes Clinical Trials Studying Complications
DCCT/EDIC Study
TIDM and Autoimmune Disorders
Immunotherapy of Type 1 Diabetes
Pathology of T2DM
Pathophysiology of Type 2 Diabetes
Pancreas
Pancreatic Alpha and Delta Cells, Pancreatic Function in Diabetes
Introduction: Pathology of Diabetes Complications
Pathology of Diabetes Complications
Incretin Therapies in T2DM
Incretin-based Therapies in Diabetes
Summary: Issues in Pediatric Diabetes
Summary: Issues in Pediatric Diabetes
Osteoporosis and Diabetes
Background: Osteoporosis and Diabetes
Overview of Pathophysiology and Treatment
Type 1 Diabetes Symptoms
Macrovascular Complications
Chronic Diabetes Complications: Macrovascular
Diabetic Nephropathy
Description: Diabetic Kidney Disease (DKD)
Summary: Pathology of Diabetes Complications
Summary: Pathology of Diabetes Complications
Microvascular Complications
Diabetic Nephropathy: Risk Factors, Treatment
Surgical Management of Diabetes
Gastric Bypass
Surgical Management of Diabetes
Gastric Bypass
T1DM (Type 1 Diabetes)
Incidence of T1DM Varies with Race
Impact of Diabetes
Deaths Attributable to Disease
Diagnosis
Hyperglycemia and Diabetes
Organs Affected by Diabetes
Reproductive System
Endocrine Glands Involved in Diabetes
Thyroid
Diabetes
Type 1 or Insulin-Dependent Diabetes Mellitus
Pathophysiology of Type 1 Diabetes
Pathophysiology of Type 1 Diabetes
Endocrine Glands Involved in Diabetes
Adrenals
Diabetic Nephropathy
Diabetic Nephropathy: Etiology
Summary: Issues in Pediatric Diabetes
Case Study: Evan - Symptoms and Solution
Relationship between Obesity, Diabetes and Cardiovascular Disease
Obesity, Diabetes and Cardiovascular Disease
Obesity: Pathophysiology of Fat Cells
Obesity...
Endocrine Glands Involved in Diabetes
Pituitary
Diabetes Annotations
AWARD-6 Study
T1DM (Type 1 Diabetes)
Glycemic Goals Across Pediatric Groups
Diabetes Annotations
Humalog Efficacy
Diabetes Annotations
AWARD-5 Study
Diabetes: Anatomy and Physiology: Summary
Diabetes: Anatomy and Physiology: Summary
Diabetes Annotations
AWARD-4 Study
Pathology of T1DM
Progression of Type 1 Diabetes
Diabetes Annotations
AWARD-2 Study
Diabetes Annotations
Lantus Summary of Product Characteristics
Type 2 Diabetes Mellitus (T2DM)
Natural History of T2DM: Summary
Prandial Insulin
Prandial
Liver
Liver Function in Diabetes, Therapy for Type 2 Diabetes
Relationship between Obesity, Diabetes, and Cardiovascular Disease
Obesity, Diabetes and Cardiovascular Disease
Type 2 Diabetes Mellitus (T2DM)
Natural History of T2DM: Summary
Summary: Diabetes: Type 1 Pathophysiology
Pathophysiology of Type 1 Diabetes
Type 2 Diabetes Mellitus (T2DM)
Natural History of T2DM: Summary
Diagnosis and Management
Diabetes Medical Management Plan (DMMP)
Relationship between Obesity, Diabetes and Cardiovascular Disease
Prevalence of Obesity in Adults Aged 20+ Years by WHO Region (2008)
Obesity and Type 2 Diabetes...
Diabetes: Patient Clinical Case Studies
Diabetes Patient Clinical Case Study: Sylvia
Diabetes: Patient Clinical Case Study
Diabetes Patient Clinical Case Study: Philippe
Diabetes: Patient Clinical Case Studies
Diabetes Patient Clinical Case Study: Sarah
Diabetes: Patient Clinical Case Studies
Diabetes Patient Clinical Case Study: Vivian
Diabetes: Patient Clinical Case Studies
Diabetes Patient Clinical Case Study: Anna
Diabetes: Patient Clinical Case Studies
Diabetes Patient Clinical Case Study: Sophie
Kidney
Kidney Function in Diabetes
Pharmaceutical Therapies for Managing Hyperglycemia
Pancreatic Hormones
Introduction: Pathophysiology of Type 2 Diabetes
Introduction: Pathophysiology of Type 2 Diabetes
Microvascular Complications
Diabetic Retinopathy: Screening
Pharmaceutical Therapies for Managing Hyperglycemia
Secretagogues
Endocrine Glands Involved in Diabetes
Pancreas: Somatostatin
Endocrine Glands Involved in Diabetes
Digestive System
Summary: Pathophysiology of Type 2 Diabetes
Summary: Pathophysiology of Type 2 Diabetes
Endocrine Glands Involved in Diabetes
Pancreas: Glucagon
Organs Affected by Diabetes
Peripheral Nervous System
Pathology of T1DM
Natural History of Type 1 Diabetes
Endocrine Glands Involved in Diabetes
Endocrine Pancreas
Endocrine Glands Involved in Diabetes
Pancreas: Insulin, Amylin
Organs Affected by Diabetes
Central Nervous System
Diabetes Patient Clinical Case Study PPT
Diabetes Patient Clinical Case Study PPT: Sarah
Diabetes Patient Clinical Case Study PPT
Diabetes Patient Clinical Case Study PPT: Vivian
Diabetes Patient Clinical Case Study PPT
Diabetes Patient Clinical Case Study PPT: Sylvia
Diabetes Patient Clinical Case Study PPT
Diabetes Patient CLinical Case Study PPT: Sophie
Diabetes Patient Clinical Case Study PPT
Diabetes Patient Clinical Case Study PPT: Anna
Basaglar T1DM: Introduction
Pathophysiology of Type 1 Diabetes Mellitus
Organs Affected by Diabetes
Muscle and Fat Tissue
Pathology of T1DM
Type 1 Diabetes Disease Pathway: Islet Autoantibodies
Epidemiology
Incidence and Prevalence: International Diabetes Federation
T1DM Overview
Type 1 Diabetes Mellitus (T1DM)
Use of Basal Insulin
Type 2 Diabetes Is a Chronic Progressive Disease
Diabetes Annotations
Humalog Delivery
Introduction to Diabetes Clinical Trial Design
Conducting and Analyzing Clinical Trials
Clinical Trials: Event Definitions
Analyzing the Results of Diabetes Trials: Relative Risk
Diabetes Clinical Trial Design: Randomized Controlled Trial (RCT) Designs
Randomized Controlled Trial (RCT)
Pharmaceutical Therapies for Managing Hyperglycemia
Secretagogues
Lantus Summary of Product Characteristics
Lantus Summary of Product Characteristics
Pharmaceutical Therapies for Managing Hyperglycemia
Pancreatic Hormones
Secretagogues
Pharmaceutical Therapies for Managing Hyperglycemia
Diabetic Nephropathy
Disease Course and Natural History
Pharmaceutical Therapies for Managing Hyperglycemia
Pancreatic Hormones
Diabetes Clinical Trial Design: Crossover Designs
Randomized Crossover Design
Selected Trials
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes (AUTONOMY)
Diabetic Nephropathy
Tubular Pathophysiology
Pharmaceutical Therapies for Managing Hyperglycemia
Secretagogues
Pathology of Type 2 Diabetes Mellitus
Causes of Elevated Blood Glucose in Type 2 Diabetes
Pharmaceutical Therapies for Managing Hyperglycemia
Secretagogues
Insulin Resistance in Type 2 Diabetes Mellitus
Insulin Resistance and Type 2 Diabetes
Pharmaceutical Therapies for Managing Hyperglycemia
Secretagogues
Diabetes Annotations
Humalog 200 units/ml KwikPen SmPC
Diabetes Annotations
Critical Appraisal
Overview of Basal Insulins
ADA Standards of Medical Care in Diabetes, ADA/EASD Consensus on Insulin Initiation, AACE Comprehens...
Phase 3 Clinical Studies
Dulaglutide: REWIND
Prandial Insulin Treatment
Guidelines for Prandial Use in T2DM
Disease State
Signs and Symptoms
Disease State
Risk Factors
Selected Trials
APOLLO Trial
Relationship between Obesity, Diabetes, and Cardiovascular Disease
Obesity and Insulin Resistance
Obesity and Dyslipidemia
Obesity and Hypertension
Obes...
Pathology of T1DM
Antigen
TIDM and Autoimmune Disorders
Heterogeneity of Type 1 Diabetes Mellitus
Relationship between Obesity, Diabetes and Cardiovascular Disease
Obesity and Youth
Muscle and Adipose Tissue
Muscle and Adipose Tissue Function in Diabetes
Relationship between Obesity, Diabetes, and Cardiovascular Disease
Obesity and Insulin Resistance
Kidney
Therapy for Type 2 Diabetes: SGLT2 Inhibitors
Diagnosis and Management
Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
Relationship between Obesity, Diabetes, and Cardiovascular Disease
Obesity and Dyslipidemia
Relationship between Obesity, Diabetes and Cardiovascular Disease
Overweight and Obesity in Youth
Pharmaceutical Therapies for Managing Hyperglycemia
Pancreatic Hormones
Pharmaceutical Therapies for Managing Hyperglycemia
Secretagogues
Gastrointestinal Tract
Therapy for Type 2 Diabetes, Stomach
Summary: Issues in Pediatric Diabetes
Case Study: Evan - Adolescence and Insulin Adjustments
Relationship between Obesity, Diabetes, and Cardiovascular Disease
Obesity and Hypertension
Pancreas
Pancreatic Beta Cells, Therapy for Type 2 Diabetes
Muscle and Adipose Tissue
Therapy for Type 2 Diabetes
Summary
Type 1 Diabetes (T1DM) Summary
Cardiovascular Measures
Electrocardiogram, Endpoints for Diabetes Studies: MACE
Clinical Trials: Statistical Analysis
Analyzing the Results of Diabetes Trials
Insulin Resistance in Type 2 Diabetes Mellitus
Insulin Resistance: Hepatic
Relationship between Obesity, Diabetes, and Cardiovascular Disease
Worldwide Rates of Overweight and Obesity
Summary: Issues in Pediatric Diabetes
Case Study: Evan - Education of Teachers and Parents
Glycemic Control Intervention in Type 2 Diabetes: 4-T
Treating To Target in Type 2 Diabetes (4-T)
Glycemic Control Intervention in Type 2 Diabetes: INITIATE
INITIATing Insulin Therapy in Type 2 DiabEtes (INITIATE)
Gastrointestinal Tract
Therapy for Type 2 Diabetes, Bariatric Surgery
Clinical Trials: Outcomes in Diabetes Trials
Clinical Trial Outcomes
Glucose Homeostasis
Organs Involved in Glucose Homeostasis and Diabetes
Diabetes Annotations
Humalog Cost
Diabetes Clinical Trial Design: Cohort Designs
Cohort Study
Underlying Mechanisms of Diabetes Complications
Endothelial Cells, Hyperglycemia
Pharmaceutical Therapies for Managing Hyperglycemia
Pharmaceutical Therapies for Managing Hyperglycemia
Pharmaceutical Therapies for Managing Hyperglycemia
Insulin Sensitizers
Endocrine Glands Involved in Diabetes
Digestive System - L-cells
T1DM Overview
Type 1 Diabetes Symptoms
Pharmaceutical Therapies for Managing Hyperglycemia
α-Glucosidase Inhibitors
Endocrine Glands Involved in Diabetes
Digestive System - K-cells
Association of Obesity, Diabetes, and Cardiovascular Disease
Obesity Trends Among U.S. Adults (BRFSS)
Pharmaceutical Therapies for Managing Hyperglycemia
Pancreatic Hormones
Diabetes Annotations
AWARD-3 Study
Use of Basal Insulin
NICE Guidelines: Blood-Glucose-Lowering Therapy for Type 2 Diabetes
Diabetes Annotations
AWARD-1 Study
Pharmaceutical Therapies for Managing Hyperglycemia
Insulin Sensitizers
Relationship between Obesity, Diabetes and Cardiovascular Disease
Obesity
Use of Basal Insulin
Need for Basal Insulin Therapy: AACE/ACE Comprehensive Diabetes Management Algorithm
Prandial Insulin Treatment
Benefits of Targeting Prandial Glucose in T2DM
Diabetes Annotations
Jardiance
Pharmaceutical Therapies for Managing Hyperglycemia
Insulin Sensitizers
Incretin Therapies in T2DM
The Incretin Effect
Diabetes Annotations
Abasaglar insulin glargine
Phase III Clinical Studies
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Disease State
Genetic Risk Factors
Clinical Trials: Overview
Clinical Trials: Overview
Pancreas
Biphasic Insulin Secretion
Overview of Pathophysiology and Treatment
Treatment Goals
Health Outcomes
Dulaglutide: AWARD-1 Reaney M., et al., 2013
Macrovascular Complications
Blood Pressure, Dyslipidemia
Diabetes Annotations
Lantus Summary of Product Characteristics
Impact of Diabetes
Proportion of Global Non-Communicable Disease Deaths Under the Age of 70 (2008)
Introduction to Basal Insulins
Introduction to Basal Insulins
Pathology of T1DM
Type 1 Diabetes: Risk Factors
Pharmaceutical Therapies for Managing Hyperglycemia
Insulin Sensitizers
GLP-1 Receptor Agonists and Weight Loss
Efficacy of Liraglutide for Weight Loss Among Patients with Type 2 Diabetes
Relationship between Obesity, Diabetes and Cardiovascular Disease
Prevalence of Obesity in Adults Aged 20+ Years by WHO Region (2008)
Glycemic Control Intervention in Type 2 Diabetes: Heart2D
Hyperglycemia and its Effect after Acute myocardial infaRction on cardiovascular outcomes in patient...
Diabetes Clinical Trial Design: Cross-Sectional Survey Designs
Cross-Sectional Survey
Insulin Resistance in Type 2 Diabetes Mellitus
Obesity and Dyslipidemia-associated Insulin Resistance
Use of Incretin Therapies in Treating Type 2 Diabetes
Overview: Benefits and Risks of Incretin-Based Medications
Aspirin and Primary Stroke Prevention
Aspirin and Stroke in Patients with Type 2 Diabetes
Diabetes Clinical Trial Design: Overview
Different Types of Study Design for Different Purposes
Glycemic Control Intervention in Type 2 Diabetes: LANMET
Insulin gLArgine or NPH combined with METformin in type 2 diabetes (LANMET)
Summary: Diabetes: Basal Insulins
Basal insulins: As a part of a basal-bolus regimen
Use of Incretin Therapies in Treating Type 2 Diabetes
Liraglutide, AWARD-4, GLP-1 receptor agonists
Endocrine Glands Involved in Diabetes
Endocrine Glands
Basaglar T1DM: Summary
Pathophysiology of Type 1 Diabetes
Basaglar T2DM: Summary
Type 2 Diabetes Mellitus
BED Disease State
Metabolic Syndrome Components: Dyslipidemia, Hypertension, and Type 2 Diabetes
Relationship between Obesity, Diabetes and Cardiovascular Disease
Obesity and the Metabolic Syndrome
Glycemic Control Intervention in Type 2 Diabetes: Treat-to-Target
Treat-to-Target Trial: Glargine and Human NPH
Diabetes Clinical Trial Design: Case Control Designs
Case Control Study
Selected Basal Insulin Clinical Trials
Complex insulin regimens
Gastrointestinal Tract
Postprandial State: The Incretin Effect
Relationship between Obesity, Diabetes and Cardiovascular Disease
Obesity and Cardiovascular Mortality
Glycemic Control Intervention in Type 2 Diabetes: DURABLE
The DURAbility of Basal Versus Lispro mix 75/25 Insulin Efficacy Trial (DURABLE)
Glycemic Control Intervention in Type 2 Diabetes: ORIGIN
The Outcome Reduction with Initial Glargine INtervention trial (ORIGIN)
Selected Trials
Results of Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes (AUTONOM...
Relationship between Obesity, Diabetes and Cardiovascular Disease
Obesity: Pathophysiology of Fat Cells
Overview of Incretin Based Therapies
GLP-1 Receptor Agonists Approved by the Federal Food and Drug Administration (FDA) and/or the Europe...
Glucose Measurement
CGMS Systems
Selected Premixed Insulin Studies
Humalog Mix25 vs. Humulin M3 in T2DM (Roach 1999)
Immunosuppressive Agents Studied
Types of Immunosuppressive Agents Studied
Pharmaceutical Therapies for Managing Hyperglycemia
Incretins
Basal Insulin
T2DM Guidelines and Position Statements Reflect Different Perspectives
Selected Premixed Insulin Studies
Humalog Mix50 (TID) vs. Humulin M3 (BID) (Schernthaner 2004)
Efficacy and Safety of Incretin Therapies in T2DM
Cancer and Pancreatitis
Pharmaceutical Therapies for Managing Hyperglycemia
Incretins
Introduction to Kidney Disease
Diabetic Nephropathy (DN)
Selected Trials
Comparison of three ways to initiate and advance insulin for type 2 diabetes
Incretin Therapies in T2DM
Effects of GLP-1 Therapy
Basal Insulin
Need for Basal Insulin Therapy
Selected Premixed Insulin Studies
Humalog Mix25 vs. Basal Insulin (Lantus) in an Insulin-naive Population with T2DM (Malone 2004)
Selected Premixed Insulin Studies
Humalog Mix25 vs. Basal Insulin (Lantus) in an Insulin-treated Population with T2DM (Malone 2005) - ...
Selected Premixed Insulin Studies
Humalog Mix50 and Humalog Mix25 (Intensive Mixture therapy) vs. Basal Insulin (Lantus) (Jacober 2006...
Transition to Adult
Transition from Pediatric to Adult Care
Glucose Measurement
CGMS Systems
Glucose Measurement
CGMS Systems
Glucose Measures: Blood Glucose
HbA1c, Anomalous HbA1c Results
Selected Premixed Insulin Studies
Humalog Mix50 (TID) vs. Basal Insulin (Lantus), Both Plus Metformin (Robbins 2007)
Clinical Trials: Overview
Clinical Trial Design: Study Phases
Therapies
Insulin Time Action Profiles
Disease State
Obesity and BMI
Epidemiology
Epidemiology: Outlook
Pharmaceutical Therapies for Managing Hyperglycemia
Incretins
Preclinical and Early Phase Studies
Background: Dulaglutide
Muscle and Adipose Tissue
Insulin Action: Muscle and Adipose
Underlying Mechanisms of Chronic Complications
Hyperglycemia and Glucotoxicity
Glucose Measurement
CGMS Systems
Health Outcomes
AWARD-3: Change in DTSQs and IW-SP
Summary
Summary: Existing and Emerging GLP-1 Therapies
Liver
Glucagon Signaling
Epidemiology
Epidemiology and Risk Factors
Selected Basal Insulin Clinical Trials
Glargine vs. Standard of Care
Phase 3 Clinical Studies
Dulaglutide: AWARD-3
Selected Trials
APOLLO Trial: Conclusions
Prandial Insulin Treatment
Alternatives for the Delivery of Insulin, Continuous Subcutaneous Insulin Infusion (CSII), Efficacy ...
Underlying Mechanisms of Chronic Complications
Hyperglycemia and Glucotoxicity
Underlying Mechanisms of Chronic Complications
Hyperglycemia and Glucotoxicity
Underlying Mechanisms of Chronic Complications
Hyperglycemia and Glucotoxicity
Underlying Mechanisms of Chronic Complications
Hyperglycemia and Glucotoxicity
Pharmaceutical Therapies for Managing Hyperglycemia
Incretins
Glucose Measurement
CGMS Systems
Types of Prandial Insulin
Rapid-Acting Insulin Analogs
Prandial Insulin Treatment
Adding Prandial Bolus
Premixed Insulin Types
Analog: Humalog Mixes
Kidney
Kidney Function
Introduction to Incretin: Learning Objectives
Introduction to Incretin: Learning Objectives
Phase 3 Clinical Studies
Dulaglutide: AWARD-2
Phase 3 Clinical Studies
Dulaglutide: AWARD-4
Underlying Mechanisms of Chronic Complications
Hyperglycemia and Glucotoxicity
Pharmaceutical Therapies for Managing Hyperglycemia
Incretins
Preclinical and Early Phase Studies
Immunogenicity Studies of Dulaglutide
Phase 3 Clinical Studies
Dulaglutide: AWARD-1
Clinical Trials: Post Completion
Publications Requirements for Clinical Trials
Endocrine Glands Involved in Diabetes
Digestive System
Digestive System - L-cells
Digestive System - K-cells
Underlying Mechanisms of Chronic Complications
Hyperglycemia and Glucotoxicity
Underlying Mechanisms of Chronic Complications
Hyperglycemia and Glucotoxicity
Liver
Liver Function
Patient Types
Types of Patients on Premixed Insulin
Kidney
Kidneys
Phase 3 Clinical Studies
Dulaglutide: AWARD-5
Endocrine Glands Involved in Diabetes
Endocrine Pancreas
Pancreas: Insulin, Amylin
Pancreas: Glucagon
Pancreas: Somatostati...
Premixed Insulin
Normal Insulin
Pharmaceutical Therapies for Managing Hyperglycemia
Incretins
Pancreas
Glucose Homeostasis
Premixed Insulin Types
Types of Premixed Insulins
Underlying Mechanisms of Chronic Complications
Hyperglycemia and Glucotoxicity
What is Biotechnology?
A Breakthrough in Treating Diabetes
Summary
A Hypothetical Case Study
Phase 3 Clinical Studies
Phase 3 Development Program
Preclinical and Early Phase Studies
Outcome of Early Phase Preclinical Development
Diabetic Nephropathy
Kidney Disease Treatment: Goals and Components
Diabetic Nephropathy
Pathophysiology
Phase 3 Clinical Studies
Conclusions from the 5 Pivotal AWARD Dulaglutide Studies
Macrovascular Complications
Blood Glucose
Glucose Measures: Blood Glucose
Correlation Between HbA1c and Estimated Average Glucose
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
Ion Channels in Diabetes: Sulfonylureas
Additional Recommendations and Position Statements
American Diabetes Association (ADA) Position Statement: Cardiovascular Disease and Risk Management
Overview of Incretin Based Therapies
Background: Incretin Biology and Treatment Goal
Conclusion
The Need for Clinical Trials
Pathology of T1DM
Autoimmune Disorders
Glycemic Endpoint Studies
Dulaglutide Phase 2 Glycemic Endpoint Studies
Selected Trials
Yki-Jarvinen H, Kotronen A. Meta-Analysis (2013)
Glucose Homeostasis
GLUT transporters
Glycemic Control Intervention in Type 2 Diabetes: Treat-to-Target Trial with Insulin Detemir versus Insulin Glargine
Treat-to-Target Trial: Insulin Detemir versus Glargine
Summary
Case Study: Evan - Summary
Selected Basal Insulin Clinical Trials
Insulin Glargine vs. Insulin Detemir
Premixed Insulin Types
Human: Humulin M3, Humulin 70/30
Patient Types
Choices in Insulin Regimens
Basic Pharmacokinetic Principles: ADME
ADME: Elimination
Liver
Liver: Molecular Players
Organs Affected by Diabetes
Organs Affected by Diabetes
Eyes
Kidneys
Peripheral Nervous System
Heart
Ce...
Diabetes Clinical Trial Summary
The Diabetes mellitus Insulin-Glucose infusion in Acute Myocardial Infarction 2 study (DIGAMI 2)
Overview of Incretin Based Therapies
GLP-1 Receptor Agonists
NPH Insulin
Intermediate-Acting Insulin
Strategies
Strategies for a Better Basal Insulin
Types of Prandial Insulin
Insulin Analogs: Humulin vs. Humalog
Glycemic Endpoint Studies
Dulaglutide Glycemic Endpoint Trials: Grunberger et al.
Types of Prandial Insulin
Regular Human and Rapid-Acting Analogs
Advantages and Disadvantages to Premixed Insulins
Advantages and Disadvantages to Premixed Insulins
Basal Insulin
Types of Basal Insulin
Clinical Trials: Minimizing Bias
Minimizing Bias, Control or Comparator Groups, Blinding
Glucose Homeostasis
Intracellular Glucose Processing
Overview of Incretins
Incretins and the Incretin Effect
Summary: Premixed Insulin Use and Efficacy
Premixed Insulin Use and Efficacy
Glycemic Endpoint Studies
Dulaglutide Glycemic Endpoint Trials: Umpierrez et al. EGO Study
Diagnosis and Management
Management of Children with T2DM
Premixed Insulin
Self-Mixing Insulin
Premixed Insulin Types
Humalog Mix25 vs. Humulin M3 and Premixtures Dosing
Basal Insulin Therapy
T1DM: Absolute Need for Insulin, T2DM: Eventual Need for Insulin
GLP-1 Receptor Agonists and Cardiovascular Events
GLP-1 Receptor Agonists: Effect of on Cardiovascular Events
GLP-1 Receptor Agonists for T2DM
Devices Developed for the Delivery of GLP-1 Receptor Agonists
Basal Insulin
Need for Basal Insulin Therapy: Daily Blood Glucose Profile
Selected Basal Insulin Clinical Trials
NPH Insulin vs. Glargine Comparator Trials
Diabetes Patient Clinical Case Study: Sam
Premix vs. Basal-Prandial
Prandial Humalog Mix50 vs. Basal/Bolus (Glargine/Lispro) Therapy
Pathology of T2DM
Signal (Neurotransmitter) Dysfunction (Brain)
Clinical Trials: Minimizing Bias
Minimizing Bias
Pathology of T2DM
Increased Glucagon Secretion (Pancreatic α Cells)
Selected Premixed Insulin Studies
Humalog Mix25 vs. Basal Insulin (Lantus) (Buse 2011)
Nervous System
Central Nervous System and Pituitary
Pathology of T2DM
Insulin Resistance: Hepatic (Liver)
Pathology of T2DM
Increased Glucose Reabsorption (Kidney)
Beta Cell Sensitivity
Calculation of Beta Cell Sensitivity
Clinical Trials: Patient Disposition
Patient Disposition
Prandial Insulin Treatment
Patient Education is Key to Success: Motivational Interviewing (MI), Overcoming Barriers
Premix vs. Basal-Prandial
Prandial Humalog Mix50 vs. Basal/Bolus (Glargine/Lispro) Therapy - Results
Challenges: Adolescent
The Patient: Issues for Early Adolescence and Young Adults
Pathology of T2DM
Decreased Glucose Uptake (Muscle)
Pathology of T2DM
Decreased Insulin Secretion (Pancreatic β Cells)
Pathology of T2DM
Decreased Incretin Effect (Intestines)
Glucose Measures: Blood Glucose
Glucose Concentrations Over Time
Clinical Trials: Minimizing Bias
Randomization
Pancreas
Beta Cell: Glucose Sensing and Insulin Release
Muscle and Adipose Tissue
Muscle and Adipose (Fat) Tissue
Preclinical and Early Phase Studies
Dulaglutide Glaesner et al. 2010 Pharmacokinetic (PK) Profile
Overview of Incretins
GLP-1 and GIP Actions
Efficacy of DPP-4 Inhibitors
Efficacy of DPP-4 Inhibitors
Basal Insulin: Glargine
Basal Insulin Analog: Lantus
Challenges: School Age
The Patient: Issues for School Age Children
Glycemic Endpoint Studies
Dulaglutide Glycemic Endpoint Trials: Umpierrez et al. EGO Study Overview
Selected Trials
Giugliano D et al. Trial
Selected Premixed Insulin Studies
Humalog Mix50 (TID) vs. Humulin M3 (BID) (Schernthaner 2004) - Results
Muscle and Adipose Tissue
Adipose Tissue: A New Endocrine Organ
Gastrointestinal Tract
GLP-1 Signaling and DPP-4
Challenges: Infants and Toddlers
The Patient: Issues for Infants and Toddlers
DPP-4 Inhibitors for T2DM
Marketed DPP-4 Inhibitors
Selected Trials
Treating-to-Target in T2DM: 4-T Study: 3-year Efficacy of Complex Insulin Regimens in T2DM
Selected Trials Summary
Summary: Human Insulin, Rapid-Acting Insulin Analogs and Benefits of Prandial Insulin
Selected Premixed Insulin Studies
Humalog Mix25 vs. Humulin M3 in T2DM (Roach 1999) - Results
Safety and Tolerability of DPP-4 Inhibitors
Safety and Tolerability of DPP-4 Inhibitors
Basal Insulin: Degludec
Basal Insulin Analog: Insulin Degludec
Pathology of T2DM
Fat Cells: Increased FFAs, Excess Lipids
Insulin Measures
Peripheral Insulin Concentration, C Peptide
Glucose Measures: Blood Glucose
Reproducibility/Comparisons
Gastrointestinal Tract
Intestinal L Cells, Other Intestinal Endocrine Cells
Preclinical and Early Phase Studies
Phase I Study with Dulaglutide Barrington et al. 2011
Selected Basal Insulin Clinical Trials
DEVOTE
Selected Premixed Insulin Studies
Humalog Mix25 vs. Basal Insulin (Lantus) in an Insulin-naive Population with T2DM Study (Malone 2004...
Selected Premixed Insulin Studies
Humalog Mix50 and Humalog Mix25 (Intensive Mixture therapy) vs. Basal Insulin (Lantus) (Jacober 2006...
Selected Premixed Insulin Studies
Humalog Mix50 (TID) vs. Basal Insulin (Lantus), Both Plus Metformin (Robbins 2007) - Results
Basic Pharmacokinetic Principles: ADME
Half-Life, Clearance, Rates of Processes
Basal Insulin Therapy
Starting Insulin Therapy in T2DM
Kidney Function: GFR
Measure of Kidney Function
Basal Insulin: Detemir
Basal Insulin Analog: Insulin Detemir
Prandial Insulin Treatment
General Dosages for Multiple Daily Injections (T1DM) and Adjusting Insulin for Daily Changes
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Primary Prevention in Individuals Without Diabetes and With LDL-C 70-189 mg/dL
Basal Insulin: Glargine
Basal Insulin Analog: Insulin Glargine
Selected Trials
Treating-to-Target in T2DM: 4-T Study: 3-year Efficacy of Complex Insulin Regimens in T2DM: Conclusi...
Selected Premixed Insulin Studies
Humalog Mix25 vs. Basal Insulin (Lantus) in an Insulin-treated Population with T2DM (Malone 2005) - ...
Selected Premixed Insulin Studies
DURABLE: Humalog Mix25 vs. Basal Insulin (Buse 2011) - Results
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Primary Prevention in Individuals With Diabetes Without Clinical ASCVD
Additional Measures: Clamp Techniques
Insulin sensitivity
Clinical Trials: Study Populations
Types of Study Populations
Cardiovascular Measures
Heart Failure in T2DM
Assessment of the Liver and Pancreas
Laboratory Assessment, Imaging Studies
Pathology of T2DM
Insulin Resistance: Hepatic (Liver)
Decreased Glucose Uptake (Muscle)
Decreased Insulin Se...
Prasugrel Clinical Trials
Diabetes Data
Prasugrel Clinical Trials
Diabetes Data: Conclusion
NPH Insulin
Long-Acting Insulin Glargine vs. Intermediate-Acting NPH Insulin
Basic Pharmacokinetic and Pharmacodynamic Parameters
Key PD Parameters from a Glucose Clamp Experiment, Pharmacodynamic Parameters in Diabetes
Selected Premixed Insulin Studies
Humalog Mix 25 (BID) vs. Basal Insulin Glargine (QD) and Prandial Insulin Lispro (QD) in an Insulin-...
Atherosclerosis: Treatments
Treatment of Atherosclerosis - Overview
Clinical Trials: Good Clinical Practice
Good Clinical Study Design
Selected Basal Insulin Clinical Trials
Insulin Degludec BEGIN Meta-Analysis
Clinical Trials: Good Clinical Practice
Good Clinical Practice (GCP)
Clinical Trials: Primary and Secondary Outcomes
Trial Design, Choosing a P Value
Premix vs. Basal-Prandial
Novomix 50 (BMI>30) or 70 (BMI≤30) at Breakfast and Lunch + Novomix 30 at Dinner Vs. Basal Pr...
Desirable Characteristics of GLP-1 Receptor Agonists
GLP-1 Receptor Agonists: Desirable Characteristics
Clinical Trials Comparing GLP-1 Receptor Agonists
Comparison of GLP-1 Receptor Agonists
Clinical Trials: Primary and Secondary Outcomes
Example of a Primary Outcome: Liraglutide vs. Sitagliptin
Efficacy and Safety of Incretin Therapies in T2DM
Comparison of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Efficacy and Safety of Incretin Therapies in T2DM
Use in Specific Populations: GLP-1 Receptor Agonists and DPP-4 Inhibitors
Basal Insulin Therapy
Why the delay in initiating insulin therapy?
Glucose Measures: Blood Glucose
Laboratory Tests Used to Measure Blood Glucose
Overview of Incretins
Glucose Only, GLP-1 Only, GLP-1 + Glucose
Comparison of GLP-1 Receptor Agonist Dulaglutide and DPP-4 Inhibitor Sitagliptin
AWARD-5
GLP-1 Receptor Agonists: Safety and Tolerability
GLP-1 Receptor Agonists: Common Adverse Events with Exenatide
Overview of Incretins
Other GLP-1 Effects on Beta Cell Function and Mass
GLP-1 Receptor Agonists for T2DM
Overview of GLP-1 Receptor Agonists
GLP-1 Receptor Agonists for T2DM
GLP-1 Receptor Agonists: Increasing Duration of Action
Selected Premixed Insulin Studies
Humalog Mix 25 (BID) vs. Basal Insulin Glargine (QD) and Prandial Insulin Lispro (QD) in an Insulin-...
Clinical Trials Comparing GLP-1 Receptor Agonists
Comparative Efficacy of GLP-1 Receptor Agonists
Glucose Measures: Self-Monitoring
Glucose Meters, SMBG, Continuous Glucose Monitoring (CGM)
Introduction to Kidney Disease
Diabetic Nephropathy (DN): Signs, Symptoms and Mortality
Pharmacokinetics and Pharmacodynamics
Pharmacokinetics of Once-Weekly Dulaglutide in Patients with Type 2 Diabetes Mellitus
Endocrine Glands Involved in Diabetes
Endocrine Glands
Endocrine Pancreas
Pancreas: Insulin, Amylin
Pancreas: Glucagon
Atherothrombosis
Superficial Plaque Erosion
HAART-Associated Adverse Clinical Events
Glucose Intolerance and Diabetes
Marketplace
Diabetes Mellitus
Diabetic Nephropathy
Treatment Components: Statins, Lovastatin and Ezetimibe
What is Biotechnology?
The History of Biotechnology
What is Biotechnology?
A Global Industry
The Evolution o...
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
Insulin Receptor
G Protein-Coupled Receptor (GPCR)
GPCR Example: GLP-1 Receptor
GPCR ...
Atherosclerosis: Treatments
Treatment of Atherosclerosis - Overview
Intervention - Medications
Intervention - Invasive...
Marketplace
Stroke
Diabetes Mellitus
Growth Defects
Anemia
Neutropenia
Hepatitis
R...
Marketplace
Stroke
Diabetes Mellitus
Growth Defects
Anemia
Neutropenia
Hepatitis
R...
HAART-Associated Adverse Clinical Events
HAART-Associated Adverse Clinical Events
Lactic Acidosis
Liver Toxicity
Glucose Intol...
Atherothrombosis
Overview: Atherothrombosis
Interactivity: Unstable Plaque
Interactivity: Thrombus Formatio...
Introduction
Introduction
Bioequivalent Concentrated Insulins
Non-Bioequivalent Insulins
Introduction to Concentrated Insulins
Introduction
Selected Trials
Introduction to Selected Trials
Introduction
Learning Objectives
Selected Premixed Insulin Studies
Premix vs. Basal-Prandial
Introduction
Learning Objectives
Introduction
Introduction
Summary
Summary
T1DM Overview
Diagnostic Role of C-Peptide
T1DM Overview
Diagnostic Criteria
Phase III Clinical Studies
Phase III Development Program
Use of Basal Insulin
Need for Basal Insulin Therapy: Initiation in T2DM
T1DM Overview
Incidence of T1DM Varies with Race
T2DM Diagnosis
Signs and Symptoms
Summary
Existing and Emerging GLP-1 Therapies
Insulin Treatment
Glycemic Goals
Definition and Classification
Spectrum of Disorders
T2DM Diagnosis
C-Peptide
T2DM Diagnosis
C-Peptide
Overview of Basal Insulins
Need for Basal Insulin Therapy
Use of Basal Insulin
Initiating Insulin: Differences by Country
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
Pharmacodynamics (PD) in Drug Discovery and Development
Glucose Homeostasis
Absorptive State, Physiologic Insulin Secretion
Overview of Basal Insulins
Need for Basal Insulin Therapy: Guidelines
Introduction
Introduction and Learning Objectives
Pathophysiology
Nephropathy
BED Disease State
Metabolic Syndrome and Metabolic Risk Factors
Overview of Basal Insulins
Pharmacokinetics of Human Insulin and Insulin Analogs
Pathology of T1DM
Autoimmune Disorders
Basic Pharmacokinetic Principles: ADME
ADME: Distribution
Overview of Basal Insulins
Need for Basal Insulin Therapy: Daily Glucose Profiles
Use of Basal Insulin
Types of Basal Insulin
Overview of Obesity
Benefits of Modest Weight Loss
Pathology of T2DM
Daily Glucose Profiles
Glucose Homeostasis
Insulin Molecular Biology
MAPK Pathway
Routes of Drug Administration: Effect on PK/PD
Constant Rate Regimens
Examples of Pharmacological Profiles: Insulins
Glucose Infusion Rates in Glucose Clamp Experiments with Long-Acting Insulins
Preclinical and Early Phase Studies
Outcome of Early Phase Development
Overview of Basal Insulins
Need for Basal Insulin Therapy
Pathophysiology
Retinopathy
Biologic Medical Products
Biologics in the Marketplace
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
Ligand-Gated Ion Channel
Definition and Classification
Disease State, Spectrum of Disorders
What is Biotechnology?
Biotech's First Success Story
Use of Basal Insulin
Types of Basal Insulin
Phase III Clinical Studies
Overview of AWARD Trials 1-6
Epidemiology
Incidence and Prevalence: National Health and Nutrition Examination Survey
Use of Basal Insulin
Basal Insulin Analog
Glucose Homeostasis
Absorptive State, Gastrointestinal (GI) tract
Glucose Homeostasis
Postabsorptive State: GI Tract Is Empty
Insulin Molecular Biology
Insulin Action: Muscle and Adipose
Insulin Molecular Biology
Insulin Action
Basic Pharmacokinetic Principles: ADME
ADME: Volume of Distribution
Basic Pharmacokinetic Principles: ADME
ADME: Metabolism
Overview of Incretin-Based Therapies
Background: Incretin-Biology
Niacin (Nicotinic Acid)
Efficacy and Safety: Word of Caution
Examples of Pharmacological Profiles: Insulins
Insulin: Pharmacological Profile, Factors Affecting Insulin Absorption
Biosimilarity
Demonstrating Biosimilarity: Glucose Clamp Studies
Non-Bioequivalent Insulins
Humulin R U-500: Real World Usage and Outcomes
Basic Pharmacokinetic Principles: ADME
Basic Pharmacokinetic (PK) Principles and Detailed Parameters
Pathophysiology
Common Complications
Definition and Classification
History and Controversy: Syndrome X and WHO Definition
Statins
Side Effects
Pathology of T1DM
Antigen
Need for Concentrated Insulins
Insulin Requirements in Obesity and Weight Classifications
Pathways and Networks
Hypothalamic-Pituitary-Adrenal (HPA) Axis and Disorders
Insulin Treatment
MDI Versus Pump Therapy
Typical Course of Plaque Psoriasis
Complications and Comorbidities of Psoriasis
VTE Comorbidities and Health-Related Quality of Life
Risk Categories for VTE
Autoimmune Disease Processes
Consequences of Autoimmune Diseases: Common Autoimmune Diseases
Atrial Fibrillation (AF)
Classification of Atrial Fibrillation (AF)
Glucose Homeostasis
Postabsorptive State, Insulin
Glucose Homeostasis
Postabsorptive State, Glycogenolysis and Gluconeogenesis
Glucose Homeostasis
Absorptive State, Physiologic Insulin Secretion
Glucose Homeostasis
Absorptive State, Physiologic Insulin Secretion
Glucose Homeostasis
Absorptive State, Insulin
Glucose Homeostasis
Postabsorptive State, Glucagon
Glucose Homeostasis
Postabsorptive State, Glucagon plus other factors
Insulin Molecular Biology
Beta cell: Glucose Sensing and Insulin Release
Incretins and Incretin-based Therapies
Incretins and Incretin-based Therapies
Need for Concentrated Insulins
Summary of the Need for Concentrated Insulins
Non-Bioequivalent Insulins
Humulin R U-500 PK/PD Study Key Points and Use of PK/PD Modeling to Evaluate Dose Regimens
Non-Bioequivalent Insulins
Compartment Models
Non-Bioequivalent Insulins
Humulin R U-500 Delivery Device
Introduction to Concentrated Insulins
Introduction to Concentrated Insulins
Biologic Medical Products
Overview: Biologic Medical Products
Biologic Medical Products
Production of a Recombinant Biologic
Biosimilar Drug Products
Introduction and Definition: Biosimilars
Government Regulation and Approval Pathways
Drug Patents and Generics
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
G Protein-Coupled Receptor (GPCR)
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
GPCR Example: GLP-1 Receptor
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
GPCR Example: Glucagon Receptor
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
Tyrosine Kinase Receptor
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
Example of a Drug Class That Does Not Act at a Receptor
Biosimilar Medical Products
Patent Cliff and Biologic Medicines in Development
Basic Pharmacokinetic Principles: ADME
Volume of Distribution (Vd)
Examples of Pharmacological Profiles: Insulins
Pharmacokinetics of Commonly-Used Insulins
Basaglar Insulin Glargine
Pharmacokinetics and Pharmacodynamics: Heise T et al. Duration of Action of 2 Insulin Glargine Produ...
Need for Concentrated Insulins
Insulin Resistance
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
Pharmacokinetics (PK) Terminology and Drug Development
Overview of Obesity
Health Consequences of Overweight and Obesity
Non-Bioequivalent Insulins
Humulin R U-500: Evaluating Dose Regimens, Clinical Pharmacology, Costs, and Adherence
Use of Basal Insulin
Types of Basal Insulin
Goals of Male Hypogonadism Replacement Therapy
Goals of Treatment for Male Hypogonadism
Pathological Angiogenesis
Diseases Associated with Uncontrolled Angiogenesis
Need for Concentrated Insulins
Insulin Requirements in Obesity
Treatment Guidelines: Introduction
Treatment Guidelines: Introduction
Glucose Homeostasis
Postabsorptive State, Prolonged Fasting
Glucose Homeostasis
Absorptive State, Incretins
Insulin Molecular Biology
Akt Pathway
Biosimilar Drug Products
Biosimilars in the Marketplace and Drug Development in the U.S.
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
Pharmacodynamics (PD)
Insulin Glargine: Lantus
Insulin Glargine: Lantus
Phase III Clinical Studies
Impact of Dulaglutide on HbA1c Levels
Use of GLP-1 Agents
Safe and Effective Use of the Ready-to-Use Pen
Bioequivalent Concentrated Insulins
Insulin Degludec U-200
Epidemiology
Risk Factors - Obesity
T2DM Diagnosis
Signs and Symptoms
Typical Course of Plaque Psoriasis
Onset, Episodes, Flare-Ups, Triggers
Complications and Comorbidities of Psoriasis
Management
Treatment Goals and Guidelines
Non-Bioequivalent Insulins
Insulin Glargine 300 U/mL EDITION Trials
Bioequivalent Concentrated Insulins
Humalog 200 Units/mL KwikPen
Bioequivalent Concentrated Insulins
Insulin Degludec 200 U/mL
Glucose Homeostasis
Understanding Bioequivalence
Basic Pharmacokinetics
Non-Bioequivalent Insulins
BIOD-531 U-400
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
Insulin Receptor
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
Drug Sites of Action: Tyrosine Kinase Receptor
Biologic Medical Products
Production of Monoclonal Antibodies
Basaglar Insulin Glargine
Pharmacokinetics and Pharmacodynamics: Phase I Duration of Action Study
Basaglar Insulin Glargine
Summary: Basaglar Insulin Glargine
Insulin Glargine: Lantus
Insulin Glargine: Lantus Overview
Epidemiology and Risk Factors
Risk Factors and Ischemic Stroke
Examples of Pharmacological Profiles: Insulins
Pharmacokinetics of Human Insulin and Insulin Analogs
Summary: Obesity Epidemic
Obesity Epidemic
Introduction to Kidney Disease
Kidney Disease State
Insulin Treatment
Adjusting Prandial Insulin for Daily Changes
Use of Basal Insulin
Insulin and IGF-1 Signaling
Glucose Homeostasis
Absorptive State: After a Meal
Insulin Molecular Biology
Insulin Action
MAPK Pathway
Akt Pathway
Non-Bioequivalent Insulins
Insulin Glargine 300 U/mL Indication
Non-Bioequivalent Insulins
Impact of 500 U/mL Insulin Therapy on Glycemic Control and Beta-Cell Function
Need for Concentrated Insulins
Insulin Requirements in Obesity
Understanding Bioequivalence
What is Bioequivalence?
Non-Bioequivalent Insulins
Humulin R U-500
Non-Bioequivalent Insulins
Humulin R U-500 PK/PD study
Concentrated Insulins: Summary
Concentrated Insulins: Summary
Biologic Medical Products
Overview: Biologics vs. Small Molecule Drugs
Biologic Medical Products
Enhancement and Variation
Biosimilar Drug Products
Demonstrating Biosimilarity: Challenges
Biosimilar Drug Products
Demonstrating Biosimilarity: Comparative Pharmacokinetics
Government Regulation and Approval Pathways
U.S. Food and Drug Administration
Biosimilar Insulin Products
Biosimilar Insulins
Basaglar Insulin Glargine
Summary of Basal Insulin Therapy
Introduction to Pharmacology, Pharmacodynamics and Pharmacokinetics
PK/PD Relationship and Drug Therapies
Overview of Obesity
Overweight/Obese Defined
Body Mass Index
Waist Circumference and Obesity
Cause of Obe...
Protease Inhibitors (PIs)
PI-Based HAART Regimen (NNRTI-Spareing)
Summary and Knowledge Check
Summary: Kidney Function
Epidemiology
Risk Factors - Other Factors
Summary: Chronic Kidney Disease
Summary: Chronic Kidney Disease
Non-Bioequivalent Insulins
Insulin Glargine U-300
Insulin Molecular Biology
Beta cell: Glucose Sensing and Insulin Release
Insulin Action: Muscle and Adipose
Insulin ...
Non-Bioequivalent Insulins
Phase I Insulin Glargine 300 U/mL PK/PD Study
Understanding Bioequivalence
Demonstrating Bioequivalence
Need for Concentrated Insulins
Insulin Concentration
Biologic Medical Products
Overview: Regulatory Definitions and Mechanism of Action
Government Regulation and Approval Pathways
European Medicines Agency (EMA)
Government Regulation and Approval Pathways
U.S. Food and Drug Administration: Regulatory Oversight
Summary: Biosimilars
Summary: Biologics and Biosimilars
Routes of Drug Administration: Effect on PK/PD
Lag Time, Characteristics of Common Routes of Drug Administration
Biosimilar Drug Products
Biosimilars in the Marketplace
Basaglar insulin glargine
Indication and Administration
Basaglar Insulin Glargine
Pharmacokinetics and Pharmacodynamics
Basaglar Insulin Glargine
Pharmacokinetics and Pharmacodynamics
Basaglar Insulin Glargine
Immunogenicity: Background
Pharmacokinetics and Pharmacodynamics
The Safety, Pharmacokinetics and Pharmacodynamics of Once-Weekly Dulaglutide in the Elderly Methods
Element-1 Trial
Complications of Atrial Fibrillation (AF)
Risk of Thromboembolism
Thromboembolic Complications
Risk of Thromboembolism
Use of Novel Oral Anticoagulants
Stroke Prevention in Atrial Fibrillation (AF)
Aspirin and Primary Stroke Prevention
Aspirin and Primary Stroke Prevention: Recommendations
Special Populations
NLA: American Indians/Alaska Natives
Atherosclerosis: Risk Factors
Risk Factors
Atherosclerosis: Risk Factors
Risk Factors
Heart Failure: Risk Factors
Risk Factors
Heart Failure: Diagnostic Tools/Biomarkers
Routine Laboratory Testing
Heart Failure: Treatments
Prevention
Autoimmune Disease Processes
The Etiology of Autoimmune Disease: Genetic Factors (Chromosomal Evidence: The Importance of HLA)
Clinical Manifestations
Complications of Cirrhosis
Summary: Psoriasis
Complications and Comorbidities of Psoriasis
Measures of Kidney Function
Measures of Kidney Function
Potentially Modifiable Risk Factors
Metabolic Syndrome, Oxidative Stress and Inflammation
Potentially Modifiable Risk Factors
Hyperlipidemia and Diet
Future Research Directions
Search for Disease Modifying Therapies
Mendelian Genetics
History of Cholesterol and Atherosclerosis
Prasugrel Clinical Trials
Recurrent Events Data: Results and Conclusion
Complications of Atrial Fibrillation (AF)
Risk Stratification: CHADS2
Pathophysiology
Pathophysiology
Epidemiology and Risk Factors
Proatherogenic Risk Factors
Atherosclerosis Contribution to Cardiovascular Diseases
Coronary Artery Disease: Heart Failure
Need for Concentrated Insulins
Daily Insulin Doses
Basaglar Insulin Glargine
Immunogenicity
Element-2 Trial
Pathophysiology
Neuropathy
Aspirin and Primary Stroke Prevention
Recommendations: Low Dose Aspirin
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Four Statin Benefit Groups
Autoimmune Disease Processes
Consequences of Autoimmune Diseases: Progression and Destruction in Autoimmune Disorders (Mechanisms...
Heart Failure: Risk Factors
Risk Factors
Traditional Immunosuppressive Therapies
Corticosteroids: Adverse Effects
What Disease States Cause Dry Mouth?
Metabolic or Immune Disorders
Summary: General Osteoporosis
Summary: General Osteoporosis
Lifestyle Modifications and Prevention
Risk Factor Modification: Exercise and Healthy Diet
Genetic Epidemiology
Analyzing Study Data: Confounding
Coronary Atherosclerosis: Overview
Inflammation and Atherosclerosis: ACS
Comorbidities and Health-Related Quality of Life in Patients with AF
Comorbidities Commonly Associated with AF
VTE Comorbidities and Health-Related Quality of Life
Comorbidities Commonly Associated with VTE
Diagnosis
Metabolic Syndrome Components: Abdominal Adiposity
Epidemiology of Heart Failure
Risk Factors for HF
Choice of Vessel Graft
Additional Factors Affecting the Choice of Vessel Graft
Total vs. Incomplete Revascularization
Total Revascularization
Clinical Presentation and Diagnosis
Presentation
Phase III Clinical Studies
Phase III Clinical Studies
Autoimmune Disease Processes
The Etiology of Autoimmune Disease
The Etiology of Autoimmune Disease: Genetic Factors (Risk)
Management of Hypertension in Special Populations
Management of Hypertension in Special Populations
Protease Inhibitors (PIs)
Protease Inhibitors (PIs)
Leading Manufacturers of Protease Inhibitors
PI-Based HAART Regi...
Diagnosis of SLE
Standard Measures of Disease Activity Used in Clinical Trials: SLICC/ACR Damage Index for SLE
Physiology
Hormones
Liver Diseases Overview
Genetic Diseases, Hereditary Hemochromatosis
Liver Diseases Overview
Fatty Liver Disease
Liver Diseases Overview
Liver Cancer
Hypersensitivity
Hypersensitivity Disorders: Type IV T-Cell-Mediated (Delayed)
Introduction to Kidney Disease
Chronic Kidney Disease
Adult and Late-Onset Hypogonadism
Overview: Adult and Late-Onset Hypogonadism
Epidemiology
Risk Factors - Genetic Predisposition
Diagnosis
Metabolic Syndrome Components: Dyslipidemia and Blood Pressure
Treatment for Neuropsychiatric Symptoms in AD
Risks versus Benefits of Antipsychotics in AD
Summary: Binge Eating Disorder (BED) Disease State
Summary: Binge Eating Disorder (BED) Disease State
Competitive Landscape
Ghrelin Modulation
Niacin (Nicotinic Acid)
Side Effects and Contraindications
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Statin Safety Recommendations
Traditional Treatments
JAK Inhibition
VTE Clinical Picture: Risk Factors and Comorbid States
Comorbid States
Definition and Classification
History and Controversy: Harmonizing the Metabolic Syndrome
Resistant Hypertension
Types of Hypertension
Diagnosis and Monitoring
Risk Assessment and Screening
Special Populations
NLA: African Americans
Special Populations
NLA: South Asians
Pathways and Networks
Pathways and Networks
Frontostriatal Network
Frontoparietal Attention Network
Mesocor...
Overview of Incretin-Based Therapies
GLP-1 Receptor Agonists Approved by the Federal Food and Drug Administration (FDA) and/or the Europe...
PK/PD of Basaglar
Autoimmune Disease Processes
The Etiology of Autoimmune Disease: Genetic Factors (Risk)
The Etiology of Autoimmune Disease: ...
Autoimmune Diseases: Introduction
Autoimmune Diseases: Introduction
SLE Treatments: Other
Other: Renal Transplantation
Autoimmune Diseases: Introduction
Autoimmune Diseases: Introduction
Epidemiology and Impact
Pathological Angiogenesis
Angiogenesis in Cancer
Thromboembolic Complications
Risk of Thromboembolism: Risk Stratification
Guidelines for Prophylactic Anticoagulant Therapy
Risk of Thromboembolism
Treatment
Special Populations with Hyperlipidemia
Nociceptive versus Neuropathic Pain
Neuropathic Pain
Comorbid Conditions
Comorbid Chronic Medical Conditions
Fibrates
Patient Benefit
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Primary Prevention in Individuals ≥21 Years of Age With LDL-C ≥190 mg/dL Without ASCVD
Special Populations
NLA: Hispanics/Latinos
Measures of Kidney Function
Blood Urea Nitrogen (BUN), Urine Protein, and Possible Causes of Proteinurina
Overview of Heart Failure
Classification of Heart Failure: Conventional Classification
Management of Hypertension
Hypertension Management Guidelines
AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Treatment Recommendations
Need for Concentrated Insulins
Insulin Concentration
Pathophysiology
Cardiovascular
Treatment Goals and Modalities
AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis Overview
Diagnosis of SLE
Standard Measures of Disease Activity Used in Clinical Trials: SLEDAI-2K
Standard Measures of D...
What Disease States Cause Dry Mouth?
Salivary Gland Disorders
Metabolic or Immune Disorders
Cancer, Radiation and Chemotherapy
SLE Treatments: Other
Other: Dialysis
Other: Renal Transplantation
Combination Therapies
Pharmacological Agents
Other Agents
Causes of Atrial Fibrillation
Atrial Fibrillation Without Associated Heart Disease - Lone AF
Complications of Atrial Fibrillation (AF)
Risk Stratification: CHADS2 Limitations
BED Disease State
Clinical Features and Complications Associated with Eating Disorders
Overview of Aspirin and Stroke
Overview of Aspirin and Stroke
Clinical Management and Treatment
STEMI: Reperfusion and Complications
Risk Factors for CHD and MI
Risk Factors
Safety
Common Adverse Effects for Atypical Antipsychotics
Statins
Efficacy and Safety: Special Populations
Ezetimibe (Zetia)
Efficacy and Safety: SHARP (Study of Heart and Renal Protection - 2011)
AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Dyslipidemia and Prevention of Atherosclerosis
AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Screening
AACE 2012 Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Follow-Up and Monitoring
Additional Recommendations and Position Statements
National Lipid Association (NLA) Recommendations for Patient-Centered Management of Dyslipidemia
Special Populations
NLA: Women
Traditional Treatments
Corticosteroids and/or Androgens
Neurology/Major Depressive Disorder Disease: Introduction
Major Depressive Disorder (MDD)
Osteoporosis and Obesity
Background
Rivaroxaban Clinical Trials: Atrial Fibrillation
ROCKET Atrial Fibrillation
Apixaban Clinical Trials: Atrial Fibrillation
ARISTOTLE Trial
Causes of Secondary Hypertension
Causes of Secondary Hypertension
Treatment
Pharmacotherapy - Statins
Risk Factors for Atherosclerosis
Risk Factors and Atherosclerosis
PCSK9 Inhibitors
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Insulin Glargine: Lantus
Efficacy: NPH Insulin versus Glargine Comparator Trials
Insulin Glargine: Lantus
Efficacy
Biosimilarity
Demonstrating Biosimilarity: Pharmacodynamics
Basaglar Insulin Glargine
Indication and Administration (EU)
Basaglar Insulin Glargine
ELEMENT Trials: Efficacy and Safety
Heart Failure: Diagnostic Tools/Biomarkers
Physical Examination
Routine Laboratory Testing
Electrocardiogram (ECG)
Chest X-Ray
Autoimmune Disease Processes
The Etiology of Autoimmune Disease
The Etiology of Autoimmune Disease: Genetic Factors (Risk)
Traditional Immunosuppressive Therapies
Corticosteroids: Immediate Effect (Anti-Inflammatory)
Corticosteroids: Gene Expression
Cor...
Summary: Psoriasis
Prevalence
Incidence
Cutaneous and Extracutaneous Manifestations
Onset, Episodes, Fla...
Dabigatran Clinical Trials: Atrial Fibrillation
RELY Study
Atopy vs. Allergy
Hypersensitivity Disorders
Association Between Atrial Fibrillation and Heart Failure
AF and HF: Overview
Biology of Eating Behaviors
Hormonal Control of Energy Homeostasis: Leptin
Special Populations
Special Populations: Introduction
Traditional Immunosuppressive Therapies
Traditional Immunosuppressive Therapies
Traditional Immunosuppressive Agents
Corticosteroi...
VTE Clinical Picture: Risk Factors and Comorbid States
Risk Factors and Comorbid States
Hypersensitivity
Type IV Hypersensitivity Reaction Subgroups
Gell-Coombs Classification
Type I Hypersensiti...
Insulin Glargine: Lantus
Safety
Insulin Glargine: Lantus
The Outcome Reduction with Initial Glargine Intervention trial (ORIGIN)
Heart Failure: Treatments
Overview
Prevention
Treatment Guidelines
Intervention - Medications
ACE Inhibito...
Marketplace
Some of the Therapeutic Areas Covered by Biologics
Introduction to Immunopathology
Autoimmune Diseases
Autoimmune Disease Processes
Epitopes and Antigenic Determinants
The Breakdown of Tolerance: The Hidden Role of Cryptic Epit...
Autoimmune Disease Processes
The Breakdown of Tolerance: The Hidden Role of Cryptic Epitopes
Adult and Late-Onset Hypogonadism
Comorbidities: Overview
Emerging Hypotheses on Treatment
Genetic Concepts: Interleukin Receptors
Introduction to Immunopathology
Autoimmune Diseases: Epidemiology and Impact
Autoimmune Diseases: General Mechanism Underlying ...
Thromboembolic Complications
Myocardial and Hemodynamic Consequences: Overview
Steroids
Glucocorticoids: Mode of Action
The Anti-Inflammatory Effects of Corticosteroids
Glucocort...
Steroids
Glucocorticoids: Side Effects
ACC/AHA Treatment Guidelines for ACS: Statistics
Diagnosis by Clinician: Treatment of UA/NSTEMI
Major Adverse Cardiac Events (MACE)
Major Adverse Cardiac Events (MACE)
Epidemiology
Longitudinal Studies: Age-Associated Diseases
Mechanisms of Autoimmune Disease: The Breakdown of Tolerance
The Breakdown of Tolerance: Molecular Mimicry
Autoimmune Disease Processes
Consequences of Autoimmune Diseases: TNF-α In Autoimmune Disease: Potential Harm OR Benefit?
Standard Agents: Overview
Vitamin K Antagonists (VKAs)
Mitochondrial Mutations
Mitochondrial Mutations
VTE Clinical Picture: Risk Factors and Comorbid States
VTE Risk Factor Classification
Thienopyridines
Prasugrel
Prasugrel Clinical Trials
Objectives: Testing the Hypothesis
Venous Thromboembolism (VTE) Clinical Picture
Risk Factors for VTE and Classification
Atherothrombosis
Platelets and Development of Atherosclerotic Lesions
Autoimmune Disease Processes
Consequences of Autoimmune Diseases: The Natural History of Autoimmune Disorders
Statistical Analysis
p-Values
Standard Agents: Therapeutic Challenges
Enoxaparin: Contraindications and Dalteparin: Warnings and Precautions
Mechanisms of Autoimmune Disease: The Breakdown of Tolerance
Mechanisms of Autoimmune Disease: The Breakdown of Tolerance
The Breakdown of Tolerance: Molecu...
Mechanisms of Autoimmune Disease: The Breakdown of Tolerance
Mechanisms of Autoimmune Disease: The Breakdown of Tolerance
The Breakdown of Tolerance: Molecu...
Pathophysiology of Male Hypogonadism
Overview: Male Hypogonadism
Standard Agents: Therapeutic Challenges
Enoxaparin: Warnings and Precautions
Standard Agents: Therapeutic Challenges
Fondaparinux: Warnings and Precautions
Hypersensitivity
Hypersensitivity: Hypersensitivity Disorders
Introduction to Concentrated Insulins: Welcome
Introduction to Concentrated Insulins: Welcome
Understanding Bioequivalence
What is Bioequivalence?
Understanding Bioequivalence
Basic Pharmacokinetics
Understanding Bioequivalence
Demonstrating Bioequivalence: Pharmacokinetics
Understanding Bioequivalence
Demonstrating Bioequivalence: Pharmacodynamics
Non-Bioequivalent Insulins
Non-Bioequivalent Concentrated Insulins
Non-Bioequivalent Insulins
Insulin Glargine 300 U/mL
Non-Bioequivalent Insulins
Humulin R U-500
Non-Bioequivalent Insulins
Humulin R U-500: Development
Non-Bioequivalent Insulins
Humulin R U-500: PK/PD study
Non-Bioequivalent Insulins
Humulin R U-500: Safety and Efficacy
Non-Bioequivalent Insulins
Humulin R U-500
Non-Bioequivalent Insulins
BIOD-531 U-400
Non-Bioequivalent Insulins
BIOD-531 U-400 Studies
Summary and Knowledge Check
Introduction to Concentrated Insulins: Summary
Bioequivalent Concentrated Insulins
Overview of Concentrated Insulins
Bioequivalent Concentrated Insulins
Bioequivalent Concentrated Insulins
Introduction to Concentrated Insulins: Welcome
Introduction to Concentrated Insulins: Welcome
Need for Concentrated Insulins
Daily Insulin Doses
Introduction: Insulin Glargine Basaglar
Introduction: Insulin Glargine Basaglar
Types of Basal Insulin
Types of Basal Insulin
Safety of Long-Acting Insulin Glargine versus Intermediate-Acting NPH Insulin
Safety of Long-Acting Insulin Glargine versus Intermediate-Acting NPH Insulin
Biosimilarity
What is Biosimilarity?
Biosimilarity
Biosimilarity: Protein Identity and Function
Biosimilarity
Demonstrating Biosimilarity
Biosimilarity
Comparative Pharmacokinetics
Basaglar insulin glargine
Basaglar insulin glargine
Basaglar insulin glargine
Overview: Basaglar insulin glargine
Basaglar insulin glargine
Pharmacokinetics and Pharmacodynamics Studies
Basaglar Insulin Glargine Basaglar
Pharmacokinetics and Pharmacodynamics: Phase 1 Studies
Basaglar Insulin Glargine
Efficacy and Safety
Basaglar Insulin Glargine
Efficacy and Safety: ELEMENT 1 Study
Basaglar Insulin Glargine
Efficacy and Safety: ELEMENT 2 Study
Basaglar Insulin Glargine
Efficacy and Safety: ELEMENT 2 T2DM Study
Basaglar Insulin Glargine
Basaglar Insulin Glargine: Introduction
Overview of Basal Insulins
Types of Basal Insulin
Insulin Glargine: Lantus
Reduced Hypoglycemia Risk with Insulin Glargine
Biosimilarity
What is Biosimilarity?
Biosimilarity
What is Biosimilarity?: Protein
Biosimilarity
What is Biosimilarity?, Demonstrating Biosimilarity
Biosimilarity
Demonstrating Biosimilarity: Comparative Pharmacokinetics
Basaglar Insulin Glargine
Overview: Basaglar Insulin Glargine
Basaglar Insulin Glargine
Overview: Basaglar and Lantus Insulin Glargine
Basaglar Insulin Glargine
Pharmacokinetics and Pharmacodynamics
Basaglar Insulin Glargine
Pharmacokinetics and Pharmacodynamics: Phase I Relative Bioavailability Study
Basaglar Insulin Glargine
Pharmacokinetics and Pharmacodynamics: Phase I Duration of Action Study
Basaglar Insulin Glargine
Results: Pharmacodynamics
Basaglar Insulin Glargine
ELEMENT 1: Efficacy and Safety
Basaglar Insulin Glargine
Efficacy and Safety: ELEMENT 2 Overview
Basaglar Insulin Glargine
Efficacy and Safety: ELEMENT 2 Endpoints
Basaglar Insulin Glargine
Efficacy and Safety: ELEMENT 2 Conclusion
Basaglar Insulin Glargine
Immunogenicity
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 1 - Moving Gallery
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 2 - Patient Case
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 3 - Injection Sites
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 4 - Label Graphs
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 5 - Patient Case
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 6 - Pen Instructions
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 7 - Glide Force
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 8 - Pen Dial
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 9 - Patient Case
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 10 - Matching
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 11 - Label Graphs
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 12 - Patient Case
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 13 - Memory
Virtual Reinforcement Humalog 200 units/mL and Insulin Treatment
Virtual Reinforcement Humalog 200 : Interaction 14 - Patient Case
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 1 - Patient Case
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 2 - GLP Receptor Agonists
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 3 - Dulaglutide
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 4 - Graph Build
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 5 - Treasure Hunt
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 6 - Crossword Puzzle
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 7 - Label Graph
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 8 - Incretin Effects
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 9 - Dose Adjustment
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 10 - Table Mistakes
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 11 - Puzzle
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 12 - AWARD Trials
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 13 - Graph Build
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 14 - Multiple Choice
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 15 - Graph Build
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 16 - AWARD Trials
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 17 - Crossword Puzzle
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 18 - Moving Gallery
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 19 - Moving Gallery
Virtual Reinforcement for Trulicity
Virtual Reinforcement for Trulicity: Interaction 20 - Trulicity Pens
Dulaglutide: Introduction
Dulaglutide: Introduction
Overview of Incretin-Based Therapies
GLP-1 Receptor Agonists
Preclinical and Early Phase Studies
Background: Dulaglutide
Preclinical and Early Phase Studies
Immunogenicity Studies of Dulaglutide
Pharmacokinetics and Pharmacodynamics
Pharmacokinetics of Once-Weekly Dulaglutide
Pharmacokinetics and Pharmacodynamics
The Pharmacokinetics of Once-Weekly Dulaglutide in Patients with Renal Impairment
Pharmacokinetics and Pharmacodynamics
The Pharmacokinetics of Once-Weekly Dulaglutide in Patients with Hepatic Impairment
Pharmacokinetics and Pharmacodynamics
Pharmacodynamics of Once-Weekly Dulaglutide
Pharmacokinetics and Pharmacodynamics
Impact of Dulaglutide on Postprandial β-Cell Function
Pharmacokinetics and Pharmacodynamics
Impact of Dulaglutide on the Absorption of Co-administered Oral Medication
Phase III Clinical Studies
Safety and Tolerability of Dulaglutide
Phase III Clinical Studies
Adverse Events of Special Interest
Phase III Clinical Studies
Vital Signs Change from Baseline
Phase III Clinical Studies
Dulaglutide and Risk for Cardiovascular Events
Phase III Clinical Studies
Summary of Safety and Tolerability Across the AWARD Program
Use of GLP-1 Agents
Safe and Effective Use of the Ready-to-Use Pen Conclusions
Introduction to Immunopathology
Organ Transplant Rejection: Class I MHC and Class II MHC Proteins
Organ Transplant Rejection: H...
Criteria for the Diagnosis of Dementia Due to Alzheimer's Disease
Differential Diagnosis
Standard Agents: Therapeutic Challenges
Therapeutic Challenges of Antithrombotic Treatment
Currently Approved Therapies: Gilenya
Gilenya
CRF
CRF and ACTH
Multiple Sclerosis
Multiple Sclerosis
Other Programs
Melanocortin Receptors
Other Programs
Melanocortin-4 Receptor
Other Programs
Chemokines
Emerging Hypotheses on Treatment
Emerging Hypotheses on Treatment: Myelination-Targeted Antibodies
Cell Therapy
Human Stem ...
view more